Drug Registration and Acceptance

Drug Name

Exact

Active Ingredient

Acceptance No.

Manufacturers

Acceptance Date

Status Date

Classification

Review Status

Drug Type

Submission

Evaluation Conclusion

ATC Category

Special Approval Varieties

Task Type

Major Special Varieties

Sequence No.

Stock Code

Visualized Analysis Export Evaluation Conclusion Evaluation Progress

Acceptance No.	Drug Name	Active Ingredient	Dosage Form	Classification	Submission	Acceptance Date	Manufacturers	Review Status	Status Date	View
JYSZ2300012	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	License Renew	2023-02-28				view
CYSB2400040	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2024-02-09	Gan & Lee Pharmaceuticals			view
CYSB2101052	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-04-27	Gan & Lee Pharmaceuticals			view
JYSB2101114	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-08-26	Sanofi-Aventis Deutschland GmbH			view
CYSB2200127	甘精胰岛素注射液	insulin glargine	Injection	Biological Products(3.3)	Supplementary Application	2022-06-02	Yichang HEC Changjiang Pharmaceutical Co Ltd			view
CYSB2300190	甘精胰岛素注射液	insulin glargine	Injection	Biological Products(3.3)	Supplementary Application	2023-10-26	Wanbang Biopharmaceuticals			view
JYSB2101151	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-10-21	Sanofi-Aventis Deutschland GmbH			view
CYSB2400141	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2024-06-01	Gan & Lee Pharmaceuticals			view
CXSS2200079	甘精胰岛素注射液	insulin glargine	Injection	Biological Products(3.3)	New Drug Application	2022-09-17	Hefei Tianmai BIOTECHNOLOGY Development Co Ltd			view
JYSB1100220	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2011-09-29	Sanofi-Aventis Deutschland GmbH	Certificate Issued	2012-08-16	view
CYSB2101250	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-11-03	Sanofi (Beijing) Pharmaceuticals Co Ltd			view
CYSB2400041	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2024-02-09	Gan & Lee Pharmaceuticals			view
CYSB2101083	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-06-03	Sanofi (Beijing) Pharmaceuticals Co Ltd			view
CYSB2101251	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-11-03	Sanofi (Beijing) Pharmaceuticals Co Ltd			view
CYSB2200117	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2022-05-18	Tonghua Dongbao Pharmaceutical Co Ltd			view
CYSB2300082	甘精胰岛素注射液	insulin glargine	Injection	Biological Products(3.4)	Supplementary Application	2023-04-13	Shandong New Time Pharmaceutical Co Ltd			view
CYSB2101050	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-04-23	Gan & Lee Pharmaceuticals			view
CYSB2400113	甘精胰岛素注射液	insulin glargine	Injection	Biological Products(3.3)	Supplementary Application	2024-05-14	Wanbang Biopharmaceuticals			view
JYSB1100219	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2011-09-29	Sanofi-Aventis Deutschland GmbH	Certificate Issued	2012-08-16	view
CYSB2101051	甘精胰岛素注射液	insulin glargine	Injection	Biological Products	Supplementary Application	2021-04-27	Gan & Lee Pharmaceuticals			view